Press release
Alzheimer's Disease Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | BioVie, AB Science, Cassava Sciences, Eli Lilly, TauRx, Novo Nordisk, KeifeRx, AriBio, Cerecin, Alzheon, Syneos Health, Athira Pharma, Annovis Bio, Anavex L
Alzheimer's Disease Market Insights
The Alzheimer's Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alzheimer's Disease pipeline products will significantly revolutionize the Alzheimer's Disease market dynamics.
DelveInsight's "Alzheimer's Disease Market Insight, Epidemiology And Market Forecast - 2034′′ report offers an in-depth understanding of the Alzheimer's Disease, historical and forecasted epidemiology as well as the Alzheimer's Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
The Alzheimer's Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Alzheimer's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Visit https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Some of the key facts of the Alzheimer's Disease Market Report:
Alzheimer's Disease market size was highest in the United States among the 7MM countries
November 2025: FDA granted Fast Track designation to BMS-986446, a tau-targeting drug candidate for treatment of early Alzheimer's disease, showing promise in altering disease progression.
October 2025: Eisai and Biogen announced FDA approval of LEQEMBI IQLIK (lecanemab-irmb) subcutaneous autoinjector for maintenance dosing in early Alzheimer's disease, enabling a convenient once-monthly dose.
July 2025: FDA approved donanemab (marketed as Kisunla by Eli Lilly) for early symptomatic Alzheimer's disease including mild cognitive impairment and mild dementia with confirmed amyloid plaques.
July 2025: ProMIS Neurosciences received FDA Fast Track designation for PMN310, a non-plaque binding therapy designed to reduce toxic amyloid-beta in Alzheimer's, aiming for improved safety and efficacy.
June 2025: Johnson & Johnson completed a $14.6 billion acquisition of Intra-Cellular Therapies, adding a Phase II oral small molecule in development for agitation and psychosis related to Alzheimer's disease.
February 2025: NKGen Biotech was granted FDA Fast Track designation for troculeucel, an autologous natural killer cell therapy for moderate Alzheimer's disease.
January 2025: FDA approved Eisai and Biogen's Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab-irmb), allowing once-monthly maintenance dosing after an 18-month initiation phase in early-stage Alzheimer's patients.
Alzheimer's Disease Companies: BioVie, AB Science, Cassava Sciences, Eli Lilly, TauRx Therapeutics, Novo Nordisk, KeifeRx, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals/Syneos Health, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, Biogen, Alzinova AB, Cognition Therapeutics, ProMIS Neurosciences, NKGen Biotech, Quest Diagnostics, GE HealthCare, Axsome Therapeutics, Amneal Pharmaceuticals, Beckman Coulter Diagnostics, BioArctic AB, Lundbeck, Otsuka Pharmaceutical, Spear Bio Inc., and Actinogen Medical Limited, among others.
Alzheimer's Disease Therapies: LEQEMBI (lecanemab), KISUNLA (donanemab), Masitinib (AB1010), Valiltramiprosate (ALZ-801), Tricaprilin (CER-0001), Bezisterim (NE3107), Galantamine, Memantine, Donepezil, Rivastigmine, Aducanumab, Brexpiprazole (REXULTI), Buntanetap, Simufilam (PTI-125), Hydromethylthionine mesylate (TRx0237), Semaglutide (NN6535), Remternetug (LY3372993), E2814, Bepranemab, GV1001, Zervimesine (CT1812), Posdinemab, PMN310, Troculeucel.
Alzheimer's Disease Overview
Alzheimer's disease is a progressive brain disorder that slowly destroys memory and thinking skills, eventually leading to the inability to perform simple tasks. It is the most common form of dementia and is characterized by the buildup of abnormal protein clumps, called plaques and tangles, in the brain that damage and kill nerve cells. While the exact cause is not fully understood, it is believed to be a combination of age, genetics, health, and lifestyle factors.
Alzheimer's Disease Market
The dynamics of the Alzheimer's Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2025-2034.
Alzheimer's Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and the views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Alzheimer's Disease Epidemiology Segmentation:
The Alzheimer's Disease market report offers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Total Diagnosed Prevalent Cases of Alzheimer's Disease
Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease
Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease
Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease
Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease
Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease
Download the report to understand which factors are driving Alzheimer's Disease epidemiology trends @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Alzheimer's Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alzheimer's Disease market or expected to get launched during the study period. The analysis covers Alzheimer's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Alzheimer's Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
To know more about Alzheimer's Disease treatment, visit @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Alzheimer's Disease Therapies and Key Companies
LEQEMBI (lecanemab): Biogen/Eisai
KISUNLA (donanemab): Eli Lilly
Masitinib (AB1010): AB Science
Valiltramiprosate (ALZ-801): Alzheon
Tricaprilin (CER-0001): Cerecin
Bezisterim (NE3107): BioVie
Galantamine: Johnson & Johnson
Memantine: Merz Pharma
Donepezil: Eisai/Pfizer
Rivastigmine: Novartis
Aducanumab: Biogen/Eisai
Brexpiprazole (REXULTI): Otsuka Pharmaceutical/Lundbeck
Buntanetap: Annovis Bio
Simufilam (PTI-125): Cassava Sciences
Hydromethylthionine mesylate (TRx0237): TauRx Therapeutics
Semaglutide (NN6535): Novo Nordisk
Remternetug (LY3372993): Eli Lilly
E2814: Eisai
Bepranemab: UCB Pharma
GV1001: GemVax & KAEL
Zervimesine (CT1812): Cognition Therapeutics
PMN310: ProMIS Neurosciences
Troculeucel: NKGen Biotech
Alzheimer's Disease Market Drivers
Growing elderly population is increasing the incidence and overall patient pool.
Emergence of disease-modifying therapies is expanding treatment opportunities.
Advances in blood-based biomarkers are improving early and accessible diagnosis.
Increasing R&D investments and strategic collaborations are accelerating pipeline growth.
Expanding adoption of PET imaging and biomarker testing is boosting diagnostic demand.
Rising healthcare spending and willingness to reimburse high-value therapies support market uptake.
Large unmet clinical need, especially in early-stage Alzheimer's, is driving therapy development.
Evolving clinical guidelines promoting earlier detection are increasing screening rates.
Adoption of AI-based cognitive assessment and monitoring tools is enhancing care pathways.
Growing economic and caregiver burden is prompting stronger policy and funding support.
Alzheimer's Disease Market Barriers
High drug costs and reimbursement uncertainties limit treatment accessibility.
Safety concerns, particularly ARIA with monoclonal antibodies, restrict broader adoption.
Limited diagnostic infrastructure and uneven access to biomarker testing hinder early detection.
Slow and complex regulatory pathways delay market entry for new therapies.
High clinical trial failure rates increase development risk and costs.
Shortage of trained neurologists reduces timely diagnosis and treatment initiation.
Patient heterogeneity and unclear disease progression complicate therapy development.
Limited awareness and stigma around cognitive decline delay patient presentation.
Challenges in large-scale screening limit identification of eligible early-stage patients.
Infrastructure and logistical constraints, such as infusion capacity, impact therapy delivery.
Scope of the Alzheimer's Disease Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Alzheimer's Disease Companies: BioVie, AB Science, Cassava Sciences, Eli Lilly, TauRx Therapeutics, Novo Nordisk, KeifeRx, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals/Syneos Health, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, Biogen, Alzinova AB, Cognition Therapeutics, ProMIS Neurosciences, NKGen Biotech, Quest Diagnostics, GE HealthCare, Axsome Therapeutics, Amneal Pharmaceuticals, Beckman Coulter Diagnostics, BioArctic AB, Lundbeck, Otsuka Pharmaceutical, Spear Bio Inc., and Actinogen Medical Limited, among others.
Key Alzheimer's Disease Therapies: LEQEMBI (lecanemab), KISUNLA (donanemab), Masitinib (AB1010), Valiltramiprosate (ALZ-801), Tricaprilin (CER-0001), Bezisterim (NE3107), Galantamine, Memantine, Donepezil, Rivastigmine, Aducanumab, Brexpiprazole (REXULTI), Buntanetap, Simufilam (PTI-125), Hydromethylthionine mesylate (TRx0237), Semaglutide (NN6535), Remternetug (LY3372993), E2814, Bepranemab, GV1001, Zervimesine (CT1812), Posdinemab, PMN310, Troculeucel.
Alzheimer's Disease Therapeutic Assessment: Alzheimer's Disease current marketed and Alzheimer's Disease emerging therapies
Alzheimer's Disease Market Dynamics: Alzheimer's Disease market drivers and Alzheimer's Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Alzheimer's Disease Market Access and Reimbursement
Discover more about therapies set to grab major Alzheimer's Disease market share @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Alzheimer's Disease Market Overview at a Glance
5. Epidemiology and Market Forecast Methodology
6. Key Events
7. Alzheimer's Disease Background and Overview
8. Alzheimer's Disease Treatment
9. Alzheimer's Disease Epidemiology and Patient Population in the 7MM
10. Alzheimer's Disease Patient Journey
11. Alzheimer's Disease Marketed Drug
12. Alzheimer's Disease Emerging Drugs
13. Alzheimer's Disease: 7MM Analysis
14. Unmet needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | BioVie, AB Science, Cassava Sciences, Eli Lilly, TauRx, Novo Nordisk, KeifeRx, AriBio, Cerecin, Alzheon, Syneos Health, Athira Pharma, Annovis Bio, Anavex L here
News-ID: 4287879 • Views: …
More Releases from delveinsight
Hunter Syndrome Pipeline Outlook Report 2025: Advancing Therapies, Drug Innovati …
DelveInsight's, "Hunter Syndrome Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hunter Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hunter Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in…
Anemia Market Growth Fueled by FDA Approvals, Improved Screening, and Expanding …
The anemia market is projected to experience significant growth across the seven major markets (7MM). This growth is driven by several factors, including increased disease awareness, improved screening practices, and expanding healthcare infrastructure dedicated to managing anemia. Key companies such as GSK, MegaPro Biomedical, Agios Pharmaceuticals, and Nemysis are leading the charge in innovation within this landscape.
DelveInsight's latest report, "Anemia - Market Insight, Epidemiology and Market Forecast - 2032," combines…
wsdfghj
asdfgh
asdfg
asdfg…
PH-ILD Market Size in the 7MM was ~USD 3 Billion in 2024 and is projected to inc …
DelveInsight's "Pulmonary Hypertension associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of PH-ILD, historical and forecasted epidemiology, as well as the PH-ILD market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Pulmonary Hypertension associated with Interstitial Lung Disease Market with DelveInsight's In-Depth Report @ Pulmonary Hypertension associated with…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
